Search for
Culture & Sensitivity, Aerobic bacteria Urethral Discharge(Vitek 2 Compact)
Bacterial/ Viral
Report in 72Hrs
At Home
No Fasting Required
Details
Identifies bacteria & antibiotic susceptibility.
₹1,036₹1,480
30% OFF
Culture & Sensitivity Aerobic bacteria Urethral Discharge (Vitek 2 Compact)
- Why is it done?
- Detects and identifies aerobic bacterial pathogens in urethral discharge samples using automated microbial identification system (Vitek 2 Compact)
- Diagnoses urethritis and sexually transmitted infections (STIs) such as gonorrhea and chlamydia
- Determines antibiotic susceptibility patterns to guide targeted antimicrobial therapy
- Evaluates patients presenting with dysuria, urethral discharge, or symptoms of urogenital infection
- Monitors treatment efficacy in documented urethral infections
- Performed when urethritis is suspected, typically during acute symptomatic phase
- Normal Range
- Negative/Normal Result: No aerobic bacterial growth detected or absence of pathogenic organisms; presence of normal flora only
- Positive/Abnormal Result: Isolation and identification of aerobic bacteria with organism name and colony count (reported as CFU/mL)
- Colony Count Interpretation: Greater than 10³-10⁴ CFU/mL typically indicates significant infection; lower counts may represent contamination
- Susceptibility Pattern: Reported as Sensitive (S), Intermediate (I), or Resistant (R) for each tested antibiotic
- Units: Colony Forming Units per milliliter (CFU/mL)
- Interpretation
- No Growth: Suggests absence of aerobic bacterial infection; may indicate viral urethritis, non-infectious urethritis, or adequate specimen collection timing
- Single Organism Isolated: Most likely represents true pathogen; common organisms include Neisseria gonorrhoeae, Chlamydia trachomatis, or other gram-negative rods
- Multiple Organisms: May indicate mixed infection, contamination, or polymicrobial urethritis; requires clinical correlation
- Antibiotic Sensitivity Results: 'S' (Sensitive) indicates organism will likely respond to therapy; 'I' (Intermediate) suggests borderline susceptibility; 'R' (Resistant) indicates treatment failure likely
- Affecting Factors: Prior antibiotic use, improper specimen collection, contamination from skin flora, timing of collection, adequate sample volume, and transport conditions affect results
- Vitek 2 Compact Technology: Provides rapid organism identification and automated susceptibility testing with high sensitivity and specificity for aerobic bacterial pathogens
- Associated Organs
- Primary Organ System: Urinary and reproductive tract (urethra, urethral glands, and adjacent structures)
- Commonly Associated Conditions: Gonorrhea (Neisseria gonorrhoeae), non-gonococcal urethritis (NGU), urethritis, sexually transmitted infections, pelvic inflammatory disease (PID) in females, epididymitis in males
- Bacterial Pathogens Identified: Neisseria gonorrhoeae, Chlamydia trachomatis (L1-L3 serovars), Mycoplasma genitalium, Ureaplasma species, Klebsiella pneumoniae, Proteus species, Staphylococcus aureus, and other gram-negative rods
- Potential Complications if Left Untreated: Ascending infection to bladder and kidneys (cystitis, pyelonephritis), prostatitis, epididymitis, orchitis, infertility, ectopic pregnancy, pelvic inflammatory disease, chronic pelvic pain, reactive arthritis, and disseminated gonococcal infection
- Secondary Involvement: Bladder, prostate, seminal vesicles, rectum, pharynx, joints, and systemic circulation in cases of disseminated infection
- Follow-up Tests
- Test of Cure (TOC): Repeat culture after completion of antimicrobial therapy (typically 1-2 weeks post-treatment) to confirm eradication
- Urinalysis and Urine Culture: To evaluate for concurrent lower and upper urinary tract infection
- Nucleic Acid Amplification Tests (NAATs): PCR/TMA testing for Chlamydia trachomatis and Neisseria gonorrhoeae for increased sensitivity
- Gram Stain Microscopy: Initial microscopic examination for presumptive identification and rapid diagnosis guidance
- Serological Testing: Antibody testing for Chlamydia trachomatis or other STI agents when indicated
- Screening of Sexual Partners: Urethral or rectal cultures and NAATs for contact tracing and prevention of transmission
- Comprehensive STI Panel: Testing for syphilis (RPR/VDRL), hepatitis B and C, HIV, HPV based on clinical presentation and risk factors
- Extended Cultures: Rectal and pharyngeal cultures if disseminated infection or extragenital symptoms suspected
- Monitoring: Clinical reassessment at 3-5 days if symptoms persist despite appropriate therapy to rule out resistance or treatment failure
- Fasting Required?
- Fasting Required: No
- Pre-Procedure Instructions: Patients should not urinate for at least 1-2 hours before specimen collection to maximize organism recovery from urethral discharge
- Specimen Collection: Sterile swab of urethral discharge collected directly from urethral meatus; separate swabs for Gram stain and culture recommended
- Medications to Avoid: Avoid topical or systemic antibiotics for minimum 48 hours prior to culture collection when possible to prevent false-negative results
- Genital Hygiene: Avoid washing genital area or douching for 24 hours before collection
- Specimen Transport: Transport to laboratory immediately in appropriate culture transport medium; maintain at room temperature and avoid refrigeration
- Processing Time: Culture results typically available in 24-72 hours; Vitek 2 Compact provides identification and susceptibility within 24 hours of positive culture growth
How our test process works!
